Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials
Open Access
- 18 October 2022
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 13 (1) , 1-23
Abstract
Purpose: Metastatic spread of prostate cancer to the skeleton may result in debilitating bone pain. In this review, we address mechanisms underpinning the pathobiology of metastatic prostate cancer induced bone pain (PCIBP) that include sensitization and sprouting of primary afferent sensory nerve fibres in bone. We also review current treatments and pain responses evoked by various treatment modalities in clinical trials in this patient population. Methods: We reviewed the literature using PubMed to identify research on the pathobiology of PCIBP. Additionally, we reviewed clinical trials of various treatment modalities in patients with PCIBP with pain response outcomes published in the past 7 years. Results: Recent clinical trials show that radionuclides, given either alone or in combination with chemotherapy, evoked favourable pain responses in many patients and a single fraction of local external beam radiation therapy was as effective as multiple fractions. However, treatment with chemotherapy, small molecule inhibitors and/or immunotherapy agents, produced variable pain responses but pain response was the primary endpoint in only one of these trials. Additionally, there were no published trials of potentially novel analgesic agents in patients with PCIBP. Conclusion: There is a knowledge gap for clinical trials of chemotherapy, small molecule inhibitors and/or immunotherapy in patients with PCIBP where pain response is the primary endpoint. Also, there are no novel analgesic agents on the horizon for the relief of PCIBP and this is an area of large unmet medical need that warrants concerted research attention.Keywords
Funding Information
- Cancer Council NSW (RG 20-06)
- Queensland Government Smart State Research Facilities Programme
- Therapeutic Innovation Australia
- Australian Government National Collaborative Research Infrastructure Strategy (NCRIS) program
This publication has 106 references indexed in Scilit:
- Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatmentsInflammopharmacology, 2013
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancerEuropean Journal of Cancer, 2012
- Breast Cancer-Induced Bone Remodeling, Skeletal Pain, and Sprouting of Sensory Nerve FibersThe Journal of Pain, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Disorders of Bone RemodelingAnnual Review of Pathology: Mechanisms of Disease, 2011
- Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer painNeuroscience, 2010
- A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: Therapeutic opportunity for treating skeletal painBone, 2010
- Bone RemodelingAnnals of the New York Academy of Sciences, 2006
- Expression and activation of αvβ3 integrins by SDF‐1/CXC12 increases the aggressiveness of prostate cancer cellsThe Prostate, 2006
- A Review of Oral Transmucosal Fentanyl Citrate: Potent, Rapid and Noninvasive Opioid AnalgesiaJournal of Palliative Medicine, 1998